

Nizoral

TRADEMARK

ketoconazole

Oral therapy for all common fungal infections

Vaginal candidosis:	In all dermatological and in systemic fungal infections:
2 tablets once daily (with food) for 5 days	1 tablet daily (with food) until complete symptomatic and mycological cure is obtained

Not all indications are as yet approved in all countries.

PRESCRIBING INFORMATION

Presentation: white, flat, half scored uncoated tablets marked "Janssen" on one side and k/200 on the reverse. Each tablet contains 200 mg ketoconazole. **Uses:** Nizoral is an orally active antimycotic for the treatment in adults, of vaginal candidosis, superficial and systemic mycoses including dermatophyte and yeast infections of the skin, hair and nails, yeast infections of the mouth and G.I. tract. Also maintenance treatment of systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children, systemic mycoses and severe local infections where previous topical treatment has failed.

Side-effects, precautions, contra-indications: contra-indicated in pregnancy. For maximal absorption, Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H₂ blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole, these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis treatment with ketoconazole should be stopped.



Janssen Pharmaceutica
B-2340 Beerse, Belgium

STATISTICS AT SQUARE ONE

by T. D. V. SWINSCOW

from the British Medical Journal


The statistical testing of data is indispensable in many types of medical investigation and a help on countless occasions in clinical practice. This book provides step-by-step instruction. Subjects covered include standard deviation, χ^2 tests, t tests, non-parametric tests and correlation. Methods specially adapted to pocket calculators.

"The ability to put symbols in sequence may well be one of the greatest advances in man's development. . . . This excellent and attractive volume will give you an idea into which category an article or projected article fits. The ink you save may be your own. It is superb value."

O'Donnell, Barry, *British Medical Journal*, 1977, 1, 451.

"... this gem of a practical booklet squeezes the essence of biostatistics into 75 well-written, well-organized pages. Newcomers to the field will like the way obscure concepts are clarified; experts will find the book valuable as a teaching aid."

de Jong, Rudolph H., *J.A.M.A.*, 1977, 237, 1874



Eighth edition

PRICE: Inland £3.00
Overseas US\$11.25*
(Inland £2.50; Overseas
US\$10.00* to BMA
members)
*including despatch by
Air Mail

Payment must be enclosed with order

ORDER YOUR COPY NOW

From: The Publisher,
British Medical Journal,
BMA House,
Tavistock Square,
London WC1H 9JR

or through any leading bookseller

The New England Journal of Medicine

Published by the Massachusetts Medical Society

Volume 352, No. 1, January 1, 2005

ISSN 0028-2718

Subscription prices: \$1200 (US and possessions), \$1300 (Canada, Mexico, and elsewhere). Single copies: \$40 (US and possessions), \$45 (Canada, Mexico, and elsewhere). Back volumes: \$1200 (US and possessions), \$1300 (Canada, Mexico, and elsewhere). Subscriptions are entered on a calendar year basis. Payment in advance. Payment may be made by check, money order, or credit card (VISA, MasterCard, American Express). Subscriptions outside the US must be paid in US dollars. Subscriptions outside the US must be paid in US dollars. Subscriptions outside the US must be paid in US dollars.

Editorial Board: **Editor:** Richard A. Hays, MD, Harvard Medical School, Boston, MA. **Associate Editor:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Section Editors:** **Internal Medicine:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Cardiology:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Neurology:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Orthopedics:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Pediatrics:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Public Health:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Statistics:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Pharmacology:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Immunology:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Microbiology:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Pathology:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Physiology:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Biophysics:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Biotechnology:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Environmental Health:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Occupational Health:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Sports Medicine:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Travel Medicine:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Geriatrics:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Endocrinology:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Nephrology:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Oncology:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Radiology:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Psychiatry:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Psychology:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Social Medicine:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Services Research:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Economics:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Law:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Policy:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Communication:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Behavior:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Equity:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Disparities:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Access:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Quality:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Safety:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Security:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Resilience:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Adaptability:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Sustainability:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Innovation:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Transformation:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Reform:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Policy:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Law:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Economics:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Communication:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Behavior:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Equity:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Disparities:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Access:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Quality:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Safety:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Security:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Resilience:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Adaptability:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Sustainability:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Innovation:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Transformation:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI. **Health Reform:** Robert M. Califf, MD, University of Michigan, Ann Arbor, MI.

Original Articles: **1** **2** **3** **4** **5** **6** **7** **8** **9** **10** **11** **12** **13** **14** **15** **16** **17** **18** **19** **20** **21** **22** **23** **24** **25** **26** **27** **28** **29** **30** **31** **32** **33** **34** **35** **36** **37** **38** **39** **40** **41** **42** **43** **44** **45** **46** **47** **48** **49** **50** **51** **52** **53** **54** **55** **56** **57** **58** **59** **60** **61** **62** **63** **64** **65** **66** **67** **68** **69** **70** **71** **72** **73** **74** **75** **76** **77** **78** **79** **80** **81** **82** **83** **84** **85** **86** **87** **88** **89** **90** **91** **92** **93** **94** **95** **96** **97** **98** **99** **100** **101** **102** **103** **104** **105** **106** **107** **108** **109** **110** **111** **112** **113** **114** **115** **116** **117** **118** **119** **120** **121** **122** **123** **124** **125** **126** **127** **128** **129** **130** **131** **132** **133** **134** **135** **136** **137** **138** **139** **140** **141** **142** **143** **144** **145** **146** **147** **148** **149** **150** **151** **152** **153** **154** **155** **156** **157** **158** **159** **160** **161** **162** **163** **164** **165** **166** **167** **168** **169** **170** **171** **172** **173** **174** **175** **176** **177** **178** **179** **180** **181** **182** **183** **184** **185** **186** **187** **188** **189** **190** **191** **192** **193** **194** **195** **196** **197** **198** **199** **200** **201** **202** **203** **204** **205** **206** **207** **208** **209** **210** **211** **212** **213** **214** **215** **216** **217** **218** **219** **220** **221** **222** **223** **224** **225** **226** **227** **228** **229** **230** **231** **232** **233** **234** **235** **236** **237** **238** **239** **240** **241** **242** **243** **244** **245** **246** **247** **248** **249** **250** **251** **252** **253** **254** **255** **256** **257** **258**

- For over 170 years, the *Journal* has been one of the world's most respected, most quoted sources of new medical knowledge — an international forum for quality research and opinion.
- The *Journal* presents original articles and interpretive reviews of a variety of developments in the major aspects of medicine: its science, its art and practice, and its position in today's society.
- Whatever your medical discipline or the stage of your career, you should subscribe to the *Journal*.

**13 Colina Road, Tottenham
London, England N15 3JA U.K.**

Name _____

Address _____

City _____

Country _____

Postal Code _____

PHYSICIANS AND ALL OTHERS	Pounds Sterling	U.S. Dollars
One year	£ 41	\$ 75
Two years	79	145
Three years	117.50	215

One year	£ 30	\$ 55
Two years	57	105
Three years	84.50	155

[illegible]

***Please allow 4-6 weeks for shipment of first issue from the time your payment is received at the NEJM. Rates are subject to change without notice.**

ABC OF HYPERTENSION

These illustrated articles on blood pressure measurement, reduction and management have now been collected together in the same format as they appeared in the *BMJ* to provide a practical guide for general practitioners and others concerned with hypertension.

*including air mail postage

**From: The Publisher, British Medical Journal, BMA House,
Tavistock Square, London WC1H 9JR
or any leading bookseller**

ABC OF HYPERTENSION

Percentage of tablets taken

Time	Percentage of tablets taken
1st day	~60
2nd day	~50
3rd day	~40
4th day	~20
5th day (leave 2 days)	~20

1st day 2nd day 3rd day 4th day 5th day (leave 2 days)

Admission After admission Follow-up

Antihypertensive treatment reduces progression

Renal failure

High blood pressure

Reduced cardiac output


Spurred ECG abnormalities

Reduced renal perfusion

Thyroid Surgery

Increased peripheral resistance

Primum non nocere



Burinex[®]

bumetanide

gentle
with
hidden
strength

Prescribing Information:— **Indications** Oedema of renal, cardiac or hepatic origin. **Dosage** Most patients require 1 mg Burinex daily given as morning or evening dose. In refractory cases dosage can be increased to achieve the desired response. For high dose treatment 5 mg Burinex should be given initially and increased by 5 mg steps at 12-24 hour intervals until desired response is achieved. **Contra-indications, Precautions and Side Effects** Contra-indicated in hepatic coma, severe electrolyte depletion and severe progressive

renal failure. Hypovolaemia and circulatory collapse may follow inappropriately excessive diuresis. Electrolyte disturbances resulting in digitalis toxicity may occur. Concurrent antihypertensive or antidiabetic therapy may require adjustment. Caution should be exercised in first trimester of pregnancy. Side effects such as skin rashes, muscular cramps, rises in serum uric acid and thrombocytopenia may rarely occur. **Product Licence Number:** 1 mg tablets 0043/0021. **Basic N.H.S. Price:** £5.60 per 100.



Leo Laboratories Limited
Longwick Road, Princes Risborough
Aylesbury, Bucks

* Burinex is a trade mark